IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

THE VESICULAR TRANSFERSOME: AN PERMEATION ENHANCER CARRIER OF LOW PERMEABILITY DRUG

[1]Mr. Vaibhavkumar Bapu Bhagwat, [2]Mr. Kharade R.G., [3]Mr. Survase A.B., [4]Mr.Ban A.A.

[1]Assistant Professor,[2] Assistant Professor,[3] Assistant Professor,[3] Assistant Professor,[4] Assistant Professor
[1]Department of Pharmaceutics,
[1]Vidya Niketan College of Pharmacy, Lakhewadi, Tal- Indapur, Dist- Pune (MH), 413103, India

Abstract: The aim of the research was to develop the Transfersomes, a novel vesicular carrier for the better activities of anti-inflammatory by reducing the gastro intestinal toxicity which associated with oral administration. Drug including Transfersomes prepared by Thin Film Hydration Techniques using surfactants is an edge activator, phospholipids and drug use in different ratios. The prepared Transfersomes were evaluated for the particle size, entrapment efficiency, zeta potential, in vitro drug release, and transmission electron microscopy. The drug and Excipients compatibility were done by using Fourier transform infrared spectroscopy [FT-IR] and found compatible with each other. The optimized batch Transfersomes were exhibit vesicle size. The optimized batch formulations of Transfersomes were incorporated in polymer and evaluated in comparison with marketed product for drug content, pH, spreadability, in vitro permeation. The deformed vesicle formed formulation exhibit better performance in combination with edge activator rather than branded formulation. Based upon the analyzed parameters such as drug release it can be concluded that transfersome formulation containing Drug provides better permeation rate in comparison to the marketed one.

IndexTerms **- Transfersomes, Deformable and Ultra Vesicles, Transdermal Route, Edge Activators, phosphatidylcholine, Stratum Corneum.**

I. INTRODUCTION

Transfersome is a stress- responsive, largely adaptable and complex total. Its preferred as an ultra deformable vesicles which enjoying an waterless core which girdled by the complex of lipid bilayer. The shape and composition of the lipid bilayer makes the vesicle as tone regulating and tone optimizing. This Transfer some enables to cross different transport of walls efficiently, and act as a medicine carrier for sustained release of remedial agents andnon-invasive targeted medicine delivery. An flexible or deformable vesicles called as elastic vesicles or the Transfersomes.[Fig. 1]. Transfersomes are phospholipids vesicles for the transdermal medicine delivery which is profitable. Because of its ultra flexible membrane and tone- optimized parcels, depending on the administration choice or operation, they're able to delivering the medicine reproducibly into or through the skin hedge with high effectiveness. The vesicular system of Transfersomes is more elastic than the ideal liposomes and thus it's more suited for skin penetration. Transfersomes reduces the skin penetration difficulty position by squeezing themselves along with the intracellular sealing lipid of stratum corneum. [1,2].

fig- transfersome



The Edge Activators used in transfersomal formulation can also enhance the solubilization of hydrophobic medicines, thereby adding the medicine ruse effectiveness of the formulation [3,4,5]. The Edge Activators has the ability to solubilize and fluidize the lipids, which result in increasing the permeation of skin [6, 7]. The effective role of Edge Activators in skin permeability depends on Edge Activators type and their concentrations. Surfactants are act as edge activators and penetrating enhancers [8]. The presence of lipophilic and hydrophilic properties in the vesicular structure resulting in huge range of solubility of Transfersomes [9, 10, 11].

➢ ADVANTAGES OF TRANSFERSOMES [12, 13, 14, 15]

- Transfersomes carriers are composed of hydrophilic and hydrophobic halves, which affect in getting a unique medicine carrier system that can deliver remedial agents with wide range of solubility.
- Transfersomes are suitable to squeeze themselves through condensation of the skin hedge that are veritably narrow, similar as 5 to 10 times lower than the vesicle periphery, owing to theirultra-deformability and elastic parcels.
- High vesicle deformability facilitates the transport of medicines across the skin without any measurable loss in complete vesicles and can be used for both topical, as well as systemic, treatments.
- Transfersomes carriers are veritably protean and effective in accommodating a variety of agents nearly independent of their size, structure, molecular weight or opposition.
- They are made up of natural phospholipids and edge activators, thus totally biocompatible and biodegradable.
- Transfersomes can be used for the delivery of key/main active composites, including proteins and peptides, insulin, corticosteroids, interferon's, anesthetics, NSAIDs, anticancer medicines and herbal medicines.
- Avoiding the first-pass metabolism, which is a major drawback in oral drug administration, and result in optimized bioavailability of the drug?
- Minimize the undesirable side effects of the drug, as well as protect the drug from metabolic degradation; moreover, the utility of short half-life drugs.
- They have the advantage of being made from pharmaceutically respectable constituents using standard styles but need to be designed and optimized on a case- by- case base.
- Due to a short and simple product procedure, it's easy to make it huge scale up.

➢ LIMITATIONS OF TRANSFERSOMES [12, 13, 16]

- Transfersomes are considered as chemically unstable due to their tendency to oxidative declination. The oxidation of Transfersomes can be significantly dropped when the waterless media is degassed and purified with inert feasts, similar as nitrogen and argon [17]. Storage at a low temperature and protection from light will also reduce the chance of oxidation [18]. Post-preparation processing, similar as snap- drying and spray- drying, can ameliorate the storehouse stability of Transfersomes[19].
- Another handicap of exercising Transfersomes as a medicine delivery system is the difficulty to achieve the chastity of natural phospholipids. thus, synthetic phospholipids could be used as druthers [20].
- The expensiveness of transfersomal phrasings is associated with the raw accoutrements used in lipid excipients, as well as the precious outfit demanded to increase manufacturing. Hence, the extensively used lipid element is phosphatidylcholine, because it's fairly low in cost [21].

➢ MECHANISM OF ACTION:

Vesicles are known as colloidal patches, which are an waterless cube enclosed by a concentric bilayer that are made- up of amphiphilic motes. They're veritably useful as vesicular medicine delivery systems, which transport hydrophilic medicines reprised in the inner waterless cube, whereas hydrophobic medicines are entangled within the lipid bilayer [22]. they are largely deformable(ultra-flexible) and tone- optimizing new medicine carrier vesicles, in which their passage across the skin is substantially associated with the Transfersomes, membrane inflexibility, hydrophilicity and the capability to maintain the vesicle's integrit [Fig. 2][23,24].

fig - the mechanism of action of transfersomes.



They efficiently access through the complete skin if applied under non occlusive conditions; this specific non occlusive state of the skin is needed substantially to initiate a trans-epidermal bibulous grade across the skin [25, 26]. transferosome's humidity-seeking tendency towards deeper skin layers rather than dry external background due to the state of humidity evaporation from the transfersomal expression following its operation on the skin (non occlusive condition) [27]. Transfersomes have some quantities of alcohol(ethanol or propylene glycol) in their compositions as penetration enhancers and, also, used as cosolvents that have good solvating power. Ethanol has been proposed to induce variations of the lipid bilayer polar head region. Following penetration, ethanol increases the fluidity of the intercellular lipid matrix and latterly on results in downing the viscosity of the lipid vesicles [28]. Transfersomes can access through the stratum corneum and reach the target spots, including the dermis and blood rotation. Their penetration capability depends on the deformability of the transfersomal membrane, which can be attributed to the vesicle compositions [29, 30]. Thus, the most suitable vesicle compositions must be linked through conducting collectively designed experimental procedures for each remedial agent to gain the most applicable carriers with optimum deformability, medicine carrying capacity and stability.

- **NEED OF THE STUDY.**

- To increase the permeation level of low permeable drugs.
- To check the Excipients compatibility with the Active Pharmaceutical Drugs whose permeatibility is low.
- To show the Effect and quality of prepared product is greater than the marketed product respectively.

- **COMPOSITION OF TRANSFERSOMES:**

Transfersomes are generally composed of,

- Originally, the main component, an amphipathic component (e.g., soy phosphatidylcholine, egg phosphatidylcholine,etc.) that can be a admixture of lipids, which are the vesicle- forming factors that produce the lipid bilayer [31,32].
- Secondly, 10 – 25 surfactants/ edge activators; the most generally used edge activators in transfersome medications are surfactants as sodium cholates; sodium deoxycholate; Tweens and Spans(Tween 20, Tween 60, Tween 80, Span 60, Span 65 and Span 80) and dipotassium glycyrrhizinate, which are biocompatible bilayer- softening composites that increase the vesicles bilayer inflexibility and ameliorate the permeability [33,34,35,36,37].
- About 3 – 10 alcohol (ethanol or methanol), as the detergent and, eventually, hydrating medium correspond with either water or a saline phosphate buffer (pH6.5 – 7) [38, 39].

II. RESEARCH METHODOLOGY

- **Rotary Evaporation-Sonication Method /Thin Film Hydration Technique**

The phospholipids and edge activator (vesicle- forming constituents) are dissolved in a round- bottom beaker using a unpredictable organic detergent admixture (illustration chloroform and methanol in a suitable (v/ v) rate). The lipophilic medicine can be incorporated in this step. In order to form a thin film, the organic detergent is faded above the lipid transition temperature under reduced pressure using a rotary vacuum evaporator. Keep it under vacuum to remove the final traces of the detergent. The deposited thin film is also doused using a buffer result with the applicable pH (illustration pH7.4) by gyration for a separate time

at the corresponding temperature. The hydrophilic medicine objectification can be done in this stage. The performing vesicles are swollen at room temperature and sonicated in a bath or inquiry sonicator to gain small vesicles. The sonicated vesicles are homogenized by extrusion through a sandwich of 200 nm to 100 nm polycarbonate membranes [12, 40].

- **Vortexing-Sonication Method**

The phospholipids, edge activator and the medicine are mixed in a phosphate buffer. The admixture is also vortexed until milky transfersomal suspense is attained. It's also sonicated, using a bath sonicator, for a separate time at room temperature and also extruded through polycarbonate membranes(illustration 450 and 220 nm) [41,42].

- **Modified Handshaking Process**

The modified handshaking system has the same introductory principle as the rotary evaporation- sonication system. In the modified handshaking process, the organic detergent, the lipophilic medicine, the phospholipids and edge activator are added in a round- bottom beaker. All the excipients should fully dissolve in the detergent and gain a clear transparent result. also, the organic detergent is removed by evaporation while handshaking rather of using the rotary vacuum evaporator. In the meantime, the round-bottom beaker is incompletely immersed in the water bath maintained at a high temperature(illustration 40 – 60 °C). A thin lipid film is also formed inside the beaker wall. The beaker is kept overnight for complete evaporation of the detergent. The formed film is also doused with the applicable buffer result with gentle shaking at a temperature above its phase transition temperature. The hydrophilic medicine objectification can be done in this stage [40].

- **Reverse-Phase Evaporation Method**

The phospholipids and edge activator are added to a round- bottom beaker and dissolved in the organic detergent admixture(illustration diethyl ether and chloroform). The lipophilic medicine can be incorporated in this step. also, the detergent is faded using rotary evaporator to gain the lipid flicks. The lipid flicks are redissolved in the organic phase substantially composed of isopropyl ether and/ or diethyl ether. latterly, the waterless phase is added to the organic phase, leading to a two- phase system. The hydrophilic medicine objectification can be done in this stage. This system is also subordinated to sonication using a bath sonicator until a homogeneous w o(water in oil painting) conflation is formed. The organic detergent is sluggishly faded using rotary evaporator to form a thick gel, which also becomes a vesicular suspension [41,42].

- **Ethanol Injection Method**

The organic phase is produced by dissolving the phospholipid, edge activator and the lipophilic medicine in ethanol with glamorous shifting for the separate time, until a clear result is attained. The waterless phase is produced by dissolving the water-answerable substances in the phosphate buffer. The hydrophilic medicine objectification can be done in this stage. Both results are hotted up to 45 – 50 °C. Latterly, the ethanolic phospholipid result is fitted dropwise into the waterless result with nonstop shifting for the separate time. Ethanol junking is done by transferring the attendant dissipation into a vacuum evaporator and also sonicating for size reduction in particles [43, 44].

III. CHARACTERIZATION OF TRANSFERSOMES

- **Vesicle Size, Zeta Potential and Morphology**

The vesicle size is one of the important parameters during transfersome medication, batch- to- batch comparison and scale- up processes. During storehouse, the changing of the vesicle size is an important variable in terms of the physical stability of the expression. Vesicles lower than 40 nm are prone to emulsion processes because of the high curve state of their bilayer membranes, whereas much larger and electroneutral transfersomes are added up through van der Waals relations due to fairly lesser membrane contact areas. Vesicle size is a factor that influences the capability to synopsize the medicine composites in transfersomes. For lipophilic and amphiphilic agents, a high lipid- to- core rate is favored, while a larger waterless core volume is preferred for the encapsulation of hydrophilic composites. Generally, the dynamic light scattering(DLS) system or photon correlation spectroscopy(PCS) can be used to determine the vesicle periphery. The vesicle's suspense can be mixed with an applicable medium, and the vesicular size measures can be attained in triplet. also, as another approach, the sample can be prepared in distilled water and filtered through a0.2 mm membrane sludge. The filtered sample is also adulterated with filtered saline to measure the size of the vesicles by DLS or PCS. also, the DLS system- associated motorized examination system by Malvern Zetasizer can be used for the determination of the vesicle size and size distribution, whereas the structural changes are observed by transmission electron microscopy(TEM). The zeta eventuality is measured by the electrophoretic mobility fashion using Malvern Zetasizer. The visualization of transfersome vesicles can be done by using the phase discrepancy microscopy or TEM [45, 46].

- **Entrapment Efficiency (%EE)**

The ruse effectiveness (EE) is the quantum of medicine entangled in the expression. The EE is determined by separating the unentrapped medicine from the vesicles using colorful ways, similar asmini-column centrifugation. In this process, direct or circular styles can be used to determine the EE. After ultracentrifugation, the direct approach would be removing the supernatant followed by dismembering the laid vesicles using a suitable detergent that's able of lysing the deposition. Latterly, the performing result can be adulterated and filtered using a hype sludge(0.22 –0.45 µm) to remove the contaminations. The medicine content is determined by employing logical styles, similar as modified high- performance liquid chromatography (HPLC) or spectrophotometrically, which depends on the logical system of the active pharmaceutical component (API) [47,48,49]. The % drug entrapment is denoted as:

DEE = (Total Drug conc. – Supernatant Drug conc.) / (Total Drug conc.) x 100%

- **Degree of Deformability**

This parameter is important, as it affects the saturation of the transfersomal expression. This study is done using pure water as the standard. The medication is passed through numerous microporous pollutants of known severance sizes between 50 to 400 nm. The flyspeck size, as well as the size distribution, is noted after each pass using DLS (Dynamic Light Scattering) measures [46, 50]. The degree of deformability is expressed as

$$D = J (rv/rp) 2$$

J = weight of the suspension which is extruded through the polycarbonate filters
rv = vesicle size after extrusion, rp = barrier pore size.

- **Transmission electron microscopy (TEM)**

Visualization of the vesicles was carried out using TEM. Sample for TEM is prepared using conventional negative- staining styles using 1 waterless PTA (Phosphotungstic Acid). For staining on a carbon- carpeted copper, a drop containing vesicles was dried, and redundant result is wiped using sludge paper. After drying, the instance is imaged as a small concave vesicle with girding darkness [51, 52].

- **Fourier Transforms Infrared Spectroscopy and Differential Scanning Calorimetry**

A discriminational calorimetry surveying study was carried out to examine the colorful lipid vesicles' thermal gets. An infrared spectroscopy study is used to determine any relations among the factors of the vesicle membrane and the medicine [53].

- **In-vitro diffusion study**

In- vitro prolixity study of elastic transfersome was estimated using Franz diffusion cell outfit. A cellophane membrane was pre-soaked for 24 h in phosphate buffer before being placed in between patron and receptor chambers. Elastic transfersome expression is placed on the sigma membrane in a patron cube. The receptor cube was filled with the needed volume of phosphate buffer and stirred with a glamorous stirrer. The aliquots of the sample are withdrawn from the receptor cube at definite time intervals and incontinently replaced with an equal volume of fresh phosphate buffer result to insure sink condition. The entire sample was anatomized using UV-Visible spectrophotometer [54].

IV. CONCLUSION

Transfersomes areultra-deformable carriers that grease the delivery of a different array of medicine motes across the skin hedge with superior efficacity compared to the conventional vesicular systems. The bibulous grade is the main driving force for the transport of transfersomes into the deeper skin layers. Importantly, transferosomes are specifically designed vesicular systems that need to be optimized in agreement with individual cases of medicines of interest to achieve the most effective phrasings and ultimate pharmacological responses. Further scientific studies associated with transfersomes may lead to new promising remedial approaches against numerous types of conditions.

V. REFERENCES

[1] Modi C.D., Bharadia P.D., "Transfersomes: New Dominants for Transdermal Drug Delivery", Am. J. PharmTech Res. vol. 2 (3), pp. 71-91, 2012.
[2] Megh R., Sivanappan R. K., "Nano Particle Based Delivery System and Proposed Application in Agriculture Engineering Practices for Agricultural Production and Water Conservation An Interdisciplinary Approach", Apple Academic Press. vol. 1(16), pp. 325-348, 2017.
[3] Duangjit S., Opanasopit P., Rojanarata T., Ngawhirunpat T. Characterization and in vitro skin permeation of meloxicam-loaded Liposomes versus Transfersomes. J. Drug Deliv. 2010;2011:1–9.
[4] Aggarwal N., Goindi S. Preparation and evaluation of antifungal efficacy of griseofulvin loaded deformable membrane vesicles in optimized guinea pig model of Microsporum canis—Dermatophytosis. Int. J. Pharm. 2012;437:277–287.
[5] Chen J., Lu W.-L., Gu W., Lu S.-S., Chen Z.-P., Cai B.-C. Skin permeation behavior of elastic liposomes: Role of formulation ingredients. Expert Opin. Drug Deliv. 2013;10:845–856.
[6] Duangjit S., Opanasopit P., Rojanarata T., Ngawhirunpat T. Effect of edge activator on characteristic and in vitro skin permeation of meloxicam loaded in elastic liposomes. Adv. Mater. Res. 2011;194:537–540.
[7] Jacob L., Anoop K.R. A review on surfactants as edge activators in ultradeformable vesicles for enhanced skin delivery. Int. J. Pharma Bio Sci. 2013;4:337–344.
[8] Kim B., Cho H.-E., Moon S.H., Ahn H.-J., Bae S., Cho H.-D., An S. Transdermal delivery systems in cosmetics. Biomed. Dermatol. 2020;4:1–12.
[9] Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: Permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit. Rev. Ther. Drug Carr. Syst. 1996;13:257–388.
[10] Pawar A.Y., Jadhav K.R., Chaudhari L.H. Transfersome: A novel technique which improves transdermal permeability. Asian J. Pharm. 2016;10:425–436.
[11] Ghai I., Chaudhary H., Ghai S., Kohli K., Kr V. A review of transdermal drug delivery using nano-vesicular carriers: Transfersomes. Recent Pat. Nanomed. 2012;2:164–171.
[12] Modi C., Bharadia P. Transfersomes: New dominants for transdermal drug delivery. Am. J. PharmTech. Res. 2012;2:71–91.
[13] Li J., Wang X., Zhang T., Wang C., Huang Z., Luo X., Deng Y. A review on phospholipids and their main applications in drug delivery systems. Asian J. Pharm. Sci. 2015;10:81–98.

[14] Moawad F.A., Ali A.A., Salem H.F. Nanotransfersomes-loaded thermosensitive in situ gel as a rectal delivery system of tizanidine HCl: Preparation, in vitro and in vivo performance. Drug Deliv. 2017;24:252–260.
[15] Bnyan R., Khan I., Ehtezazi T., Saleem I., Gordon S., Neill F.O., Roberts M. Surfactant effects on lipid-based vesicles properties. J. Pharm. Sci. 2018;107:1237–1246.
[16] Kumar A. Transferosome: A recent approach for transdermal drug delivery. J. Drug Deliv. Ther. 2018;8:100–104.
[17] MirAfzali Z., Thompson C.S., Tallua K. Microencapsulation in the Food Industry: A Practical Implementation Guide. Academic Press; Cambridge, MA, USA: 2014. Chapter 13—Application of liposomes in the food industry; pp. 139–150.
[18] Grit M., Crommelin D.J. Chemical stability of liposomes: Implications for their physical stability. Chem. Phys. Lipids. 1993;64:3–18.
[19] Iskandarsyah, Rahmi A.D., Pangesti D.M. Comparison of the characteristics of transfersomes and protransfersomes containing azelaic acid. J. Young-Pharm. 2018;10:S11–S15.
[20] Van Hoogevest P., Wendel A. The use of natural and synthetic phospholipids as pharmaceutical excipients. Eur. J. Lipid Sci. Technol. 2014;116:1088–1107.
[21] Yadav D., Sandeep K., Pandey D., Dutta R.K. Liposomes for drug delivery. J. Biotechnol. Biomater. 2017;7:1–8.
[22] Mathur M. Approaches for improving the pharmacological and pharmacokinetics properties of herbal drugs. Int. Res. J. Pharm. Appl. Sci. 2013;3:40–50.
[23] Jadupati M., Kumar N.A. Transferosome: An opportunistic carrier for transdermal drug delivery system. Int. Res. J. Pharm. 2012;3:35–38.
[24] Cevc G., Blume G., Schätzlein A., Gebauer D., Paul A. The skin: A pathway for systemic treatment with patches and lipid-based agent carriers. Adv. Drug Deliv. Rev. 1996;18:349–378.
[25] Chaurasiya P., Ganju E., Upmanyu N., Ray S.K., Jain P. Transfersomes: A novel technique for transdermal drug delivery. J. Drug Deliv. Ther. 2019;9:279–285.
[26] Cevc G. Transdermal drug delivery of insulin with ultradeformable carriers. Clin. Pharmacokinet. 2003;42:461–474.
[27] Mandal U.K., Mahmood S., Taher M. Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application. Int. J. Nanomed. 2014;9:4331–4346.
[28] Kumar G.P., Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery—An overview. Acta Pharm. Sin. B. 2011; 1:208–219.
[29] Cipolla D., Wu H., Gonda I., Eastman S., Redelmeier T., Chan H.-K. Modifying the release properties of liposomes toward personalized medicine. J. Pharm. Sci. 2014; 103:1851–1862.
[30] Dudhipala N., Mohammed R.P., Youssef A.A.A., Banala N. Effect of lipid and edge activator concentration on development of Aceclofenac loaded transfersomes gel for transdermal application: In vitro and ex vivo skin permeation. Drug Dev. Ind. Pharm. 2020; 46:1–28.
[31] Jiang T., Wang T., Li T., Ma Y., Shen S., He B., Mo R. Enhanced transdermal drug delivery by transfersome-embedded oligopeptide hydrogel for topical chemotherapy of melanoma. ACS Nano. 2018; 12:9693–9701.
[32] Iskandarsyah, Rahmi A.D., Pangesti D.M. Comparison of the characteristics of transfersomes and protransfersomes containing azelaic acid. J. Young-Pharm. 2018; 10:S11–S15.
[33] Jain A.K., Kumar F. Transfersomes: Ultradeformable vesicles for transdermal drug delivery. Asian J. Biomater. Res. 2017;3:1–13.
[34] Rajan R., Jose S., Mukund V.P.B., Vasudevan D.T. Transferosomes—A vesicular transdermal delivery system for enhanced drug permeation. J. Adv. Pharm. Technol. Res. 2011; 2:138–143.
[35] Jiang T., Wang T., Li T., Ma Y., Shen S., He B., Mo R. Enhanced transdermal drug delivery by transfersome-embedded oligopeptide hydrogel for topical chemotherapy of melanoma. ACS Nano. 2018; 12:9693–9701.
[36] Kotla N.G., Chandrasekar B., Rooney P., Sivaraman G., Larrañaga A., Krishna K.V., Pandit A., Rochev Y. Biomimetic lipid-based nanosystems for enhanced dermal delivery of drugs and bioactive agents. ACS Biomater. Sci. Eng. 2017; 3:1262–1272.
[37] Ascenso A., Batista C., Cardoso P., Mendes T., Praça F.G., Bentley M.V.L.B., Raposo S., Simões S. Development, characterization, and skin delivery studies of related ultradeformable vesicles: Transfersomes, ethosomes, and transethosomes. Int. J. Nanomed. 2015; 10:5837–5851.
[38] Pawar A.Y., Jadhav K.R., Chaudhari L.H. Transfersome: A novel technique which improves transdermal permeability. Asian J. Pharm. 2016; 10:425–436.
[39] Garg V., Singh H., Bimbrawh S., Singh S.K., Gulati M., Vaidya Y., Kaur P. Ethosomes and transfersomes: Principles, perspectives and practices. Curr. Drug Deliv. 2016; 14:613–633.
[40] Kadu S.D.P. Transfersomes—A boon for transdermal delivery. Indo Am. J. Pharm. Sci. 2017; 4:2908–2919.
[41] El Zaafarany G.M., Awad G.A.S., Holayel S.M., Mortada N. Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. Int. J. Pharm. 2010; 397:164–172.
[42] Sharma V., Yusuf M., Pathak K. Nanovesicles for transdermal delivery of felodipine: Development, characterization, and pharmacokinetics. Int. J. Pharm. Investig. 2014; 4:119–130.
[43] Yang Y., Ou R., Guan S., Ye X., Hu B., Zhang Y., Lu S., Zhou Y., Yuan Z., Zhang J., et al. A novel drug delivery gel of terbinafine hydrochloride with high penetration for external use. Drug Deliv. 2014; 22:1–8.
[44] Balata G.F., Faisal M.M., Elghamry H.A., Sabry S.A. Preparation and characterization of ivabradine HCl transfersomes for enhanced transdermal delivery. J. Drug Deliv. Sci. Technol. 2020; 60:101921.
[45] Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: Permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit. Rev. Ther. Drug Carr. Syst. 1996; 13:257–388.
[46] Chauhan P., Tyagi B.K. Herbal novel drug delivery systems and transfersomes. J. Drug Deliv. Ther. 2018; 8:162–168.
[47] Qushawy M., Nasr A., Abd-Alhaseeb M., Swidan S. Design, optimization and characterization of a transfersomal gel using miconazole nitrate for the treatment of candida skin infections. Pharmaceutics. 2018; 10:26.
[48] Ahad A., Al-Saleh A.A., Al-Mohizea A.M., Al-Jenoobi F.I., Raish M., Yassin A.E.B., Alam M.A. Formulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate. Saudi Pharm. J. 2017; 25:1040–1046.

[49] Bnyan R., Khan I., Ehtezazi T., Saleem I., Gordon S., O'Neill F., Roberts M. Formulation and optimisation of novel transfersomes for sustained release of local anaesthetic. J. Pharm. Pharmacol. 2019; 71:1508–1519.
[50] Jain A.K., Kumar F. Transfersomes: Ultradeformable vesicles for transdermal drug delivery. Asian J. Biomater. Res. 2017; 3:1–13.
[51] Hadidi N, Saffari M, Faizi M. Optimized transferosomal bovine lactoferrin (BLF) as a promising novel non-invasive topical treatment for genital warts caused by human papiluma virus (HPV) Iran. J. Pharm. Res. . 2018; 17:12–23.
[52] Guo F, Wang J, Ma M, Tan F, Li N. Skin targeted lipid vesicles as novel nano-carrier of ketoconazole : characterization , in vitro and in-vivo evaluation. J. Mater. Sci. Mater. Med. . . 2015; 26:1–13.
[53] Abdellatif AMM, Khalil IA, Khalil AF. Sertaconazole nitrate loaded nanovesicular systems for targeting skin fungal infection : in-vitro, ex-vivo and in-vivo evaluation. Int. J. Pharm. . . . 2017; 527:1–11.
[54] Ganem A, Quintanar D, Nava G, Mendoza N, Mendoza L, Piñón E. Formulation and in-vitro, ex-vivo and in-vivo evaluation of elastic liposomes for transdermal delivery of ketorolac tromethamine. Pharmaceutics. 2011; 3:954–70.